Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension - Trial NCT06409026
Access comprehensive clinical trial information for NCT06409026 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 21 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mayo Clinic
Timeline & Enrollment
Phase 4
May 01, 2024
Feb 01, 2025
Primary Outcome
Pulmonary arterial mean pressure/Cardiac Output (PA/CO) at peak exercise
Summary
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the
 functioning of the heart and improves quality of life.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06409026
Non-Device Trial